)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
China Resources Pharmaceutical Group
China Resources Pharmaceutical Group (3320) investor relations material
China Resources Pharmaceutical Group H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary24 Aug, 2026
Executive summary
Maintained leading position in China's pharmaceutical industry, ranking second in manufacturing and third in distribution by revenue for H1 2026.
Revenue rose 2.0% year-over-year to RMB134,457.6 million for the six months ended 30 June 2026, with net profit at RMB5,023.5 million, down 0.6% year-over-year.
Focused on R&D innovation, external M&A, digital transformation, and green development to drive high-quality, sustainable growth.
Enhanced business structure and operational quality, with strategic expansion in emerging industries and international markets.
Interim dividend declared at RMB0.087 per share, a 21% increase year-over-year.
Financial highlights
Total revenue reached RMB134,457.6 million, up 2.0% year-over-year; gross profit was RMB21,534.1 million, up 0.1%.
Net profit was RMB5,023.5 million, down 0.6% year-over-year; profit attributable to owners/shareholders rose 5.3% to RMB2,186.6 million.
Basic EPS was RMB0.35 (vs. RMB0.33 in H1 2025); interim dividend declared at RMB0.087 per share, up 21%.
Pharmaceutical manufacturing revenue: RMB24,444.7 million (-1.5% YoY), gross margin 60.3% (+1.0ppt).
Distribution revenue: RMB110,994.8 million (+2.5% YoY), gross margin 5.7% (-0.2ppt); retail revenue: RMB6,337.2 million (+14.9% YoY), gross margin 6.3% (+0.2ppt).
Outlook and guidance
Will focus on strategic emerging industries (biologics, blood products, high-end medical devices, synthetic biology) and optimize business structure.
Plans to strengthen R&D, accelerate innovation, and pursue both internal quality improvement and external expansion.
Aims to consolidate industry position, enhance operational excellence, and leverage digital technologies for business upgrades.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from China Resources Pharmaceutical Group
- Net profit up 14.9% on 4.6% revenue growth, with improved margins and higher dividend.3320
H2 2025 - Revenue up 2.5% YoY, net profit down 8.8%, strong segment growth and innovation focus.3320H1 2025
- Revenue and net profit rose 10.2% with strong segment growth and first interim dividend declared.3320H1 2024
- Revenue and net profit rose, driven by strong pharma, R&D, and digital transformation.3320H2 2024
Next China Resources Pharmaceutical Group earnings date
H2 202623 Mar, 2027
China Resources Pharmaceutical Group
Next China Resources Pharmaceutical Group earnings date
H2 202623 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
China Resources Pharmaceutical Group Limited is engaged in the manufacturing, distribution, and retail of pharmaceutical and healthcare products. The company’s business spans the production of Chinese and Western medicines, the distribution of medical devices and equipment, and the operation of retail pharmacy chains. The company is headquartered in Hong Kong, China, and its shares are listed on the SEHK.